Rami Levi may not be cheapest

Director-general of the Rami Levi supermarket chain, Rami Levi is being accused of false advertising, by the Overseer of Consumer Protection.

By MATTHEW KRIEGER
December 25, 2007 09:52

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The Overseer of Consumer Protection in the Industry, Trade and Labor Ministry, attorney Yitzhak Kimche, told the director-general of the Rami Levi supermarket chain, Rami Levi, on Monday, that he must either remove the signs from his stores advertising the lowest prices in the country or effectively prove that every single item in his stores is, in fact, priced lower than identical items in all of the country's food retailers. "This is something extremely difficult to do and until it is done, Rami Levi may be advertising falsely," Kimche said.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS